| 000 | 01531 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513094728.0 | ||
| 264 | 0 | _c19960923 | |
| 008 | 199609s 0 0 eng d | ||
| 022 | _a0031-6970 | ||
| 024 | 7 |
_a10.1007/BF00192362 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLawson, D H | |
| 245 | 0 | 0 |
_aEuropean postmarketing surveillance of ramipril in hypertension. 1. Feasibility and study cohort. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical pharmacology _c1995 |
||
| 300 |
_a73-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAngiotensin-Converting Enzyme Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aBelgium |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aFeasibility Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGermany |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNetherlands |
| 650 | 0 | 4 | _aProduct Surveillance, Postmarketing |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aRamipril _xadverse effects |
| 650 | 0 | 4 | _aUnited Kingdom |
| 700 | 1 | _aBridgman, K | |
| 700 | 1 | _ade Bock, G H | |
| 700 | 1 | _aGrobbee, D E | |
| 700 | 1 | _aHense, H W | |
| 700 | 1 | _aBlock, P | |
| 700 | 1 | _aPaterson, K R | |
| 700 | 1 | _aStonier, P | |
| 773 | 0 |
_tEuropean journal of clinical pharmacology _gvol. 49 _gno. 1-2 _gp. 73-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/BF00192362 _zAvailable from publisher's website |
| 999 |
_c8748031 _d8748031 |
||